Plain-English translation of NCT06405113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing a combination of three treatments for advanced stomach cancer: a fecal microbiota transplant (FMT, which involves transplanting healthy bacteria from a donor's stool), chemotherapy drugs called SOX, and an immunotherapy medication called Sintilimab. Researchers want to see if adding the fecal microbiota transplant to the standard chemotherapy and immunotherapy combination can help patients live longer and have better outcomes than chemotherapy and immunotherapy alone.
Advanced stomach cancer is difficult to treat, and current standard treatments don't work well enough for all patients. Scientists believe that the bacteria in your gut may play an important role in how well immunotherapy works, so adding a healthy bacterial transplant might make this treatment more effective.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new three-part treatment (fecal microbiota transplant, chemotherapy, and immunotherapy) or the standard two-part treatment (chemotherapy and immunotherapy alone). You'll receive 4–6 cycles of initial treatment at one of 15 hospitals involved in the study. If your cancer doesn't get worse, you'll move to a maintenance phase with a different medication combination until your cancer progresses, you can no longer tolerate the treatment, or the study ends. Throughout the study, you'll have regular hospital visits for treatment administration, blood tests, and scans to monitor your response.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China